DRTS · Alpha Tau Medical Ltd.

This 6-K filing announces an upcoming investor event focused on preliminary clinical data from the REGAIN trial, a small U.S. investigator-initiated study evaluating Alpha DaRT in recurrent glioblastoma. The disclosure centers exclusively on the initiation of data sharing—not results themselves—making it a forward-looking milestone rather than a definitive clinical outcome. With only three patients treated to date in a planned ten-patient feasibility study, the interim analysis is inherently exploratory and carries no statistical power; Alpha Tau explicitly states the primary objectives are safety and feasibility, not efficacy. The trial’s narrow eligibility criteria—recurrent GBM, no surgical option, prior CNS radiation—highlight both the severity of the patient population and the high regulatory and clinical bar for subsequent development. While no financial, operational, or executive changes are disclosed, the timing and framing suggest this data readout may serve as a catalyst for future discussions with regulators, potential partnership interest, or refinement of the broader clinical strategy. However, the filing contains no guidance, no updated timelines beyond the May 11 call, and no disclosure of adverse events or outcomes—limiting near-term actionable insight for investors.